Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Actin vs Kin Meds

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.0

Actin

Best for affordable compounded semaglutide with B12 enhancement
★★★3.5

Starting at $133/mo

Compounded SemaglutideB12 Enhanced
Visit Actin
7.3

Kin Meds

Best for patients who want both compounded and brand-name GLP-1 options on one platform with publicly-disclosed pricing, plus a multi-modality longevity stack — willing to verify the actual brand-name dispensing pathway during intake (whether $149 reflects commercial insurance + manufacturer savings card or a different mechanism)
★★★3.7

Starting at $149/mo

CompoundedBrand NameSemaglutideTirzepatide
Visit Kin Meds

Side-by-Side Comparison

FeatureActinKin Meds
Overall Score7.0/107.3/10
Starting Price$133/mo$149/mo
Editorial Rating3.5 ★ /53.7 ★ /5
Features2 features12 features
States Available00
Compounded✓ Yes✓ Yes
Brand Name✓ Yes
FSA/HSA Accepted
FDA WarningsNoneNone

Pros & Cons

Actin

Pros

  • Semaglutide + B12 combination for added energy support
  • Transparent pricing — exact cost shown upfront with no hidden fees
  • Competitive starting price from $133

Cons

  • Semaglutide only — no tirzepatide or liraglutide
  • No visible LegitScript or PCAB accreditation
  • State availability not disclosed
  • Broader platform (hormones, sexual wellness, hair health)

Kin Meds

Pros

  • $199/mo compounded semaglutide and $249/mo compounded tirzepatide are publicly disclosed (uncommon pricing transparency)
  • Brand-name medications offered alongside compounded — Wegovy injection + pill, Zepbound, Foundayo all listed at $149/mo entry pricing (likely the manufacturer copay-card price for commercially insured patients)
  • LegitScript verification seal displayed
  • Verbatim regulatory disclosure clearly identifies Kin Meds as the telehealth/intake platform and the 'licensed third-party pharmacy' as the dispenser — material YMYL transparency
  • Multi-modality longevity menu (Sermorelin, NAD+, Glutathione) plus TRT + hair + skin + sexual health for cross-product retention
  • Telehealth flow (questionnaire → provider review → tailored plan → ongoing support) clearly disclosed

Cons

  • Specific legal entity name + state of incorporation NOT publicly disclosed
  • Specific 'licensed third-party pharmacy' partner NOT named (verbatim disclosure acknowledges Kin Meds is NOT itself a state-licensed pharmacy)
  • Per-state availability NOT enumerated
  • $149/mo brand-name pricing for Wegovy/Zepbound/Foundayo is the entry tier — typical floors are commercial-insurance-with-savings-card; cash-pay patients should expect higher real-world costs (NovoCare $299 sema, LillyDirect $299-$449 tirz)
  • First-month promotional pricing NOT disclosed
  • Lab work + dose-titration support NOT clearly disclosed in marketing copy
  • Multi-product breadth (8+ categories) signals broad DTC telehealth rather than GLP-1-specialist platform

Our Verdict

Winner: Kin MedsScore: 7.3/10

Kin Meds edges out Actin with a higher overall score of 7.3/10 and is particularly strong for patients who want both compounded and brand-name GLP-1 options on one platform with publicly-disclosed pricing, plus a multi-modality longevity stack — willing to verify the actual brand-name dispensing pathway during intake (whether $149 reflects commercial insurance + manufacturer savings card or a different mechanism). Actin remains a solid alternative, especially if you're looking for affordable compounded semaglutide with B12 enhancement.

Glossary references

Key terms in this article, linked to their canonical definitions.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.